Berberine/Verteporfin Nanomicelles Enable O2-Economized Photodynamic Immunotherapy in Esophageal Cancer Via Tumor Metabolic Remodeling
ACS Applied Materials & Interfaces · 12.11.2026
DOI: 10.1021/acsami.6c17195 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 12.11.2026. Verfasst von Bingkun Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fujian Medical University, Fuzhou350122, China. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, Fujian Provincial Department of Science and Technology.
Abstract (Originalsprache)
Photodynamic therapy (PDT) can convert oxidative damage into systemic antitumor immunity, but mitochondrial oxygen consumption, lactate accumulation, and aberrant angiogenesis create a hypoxic and immunosuppressive tumor microenvironment that limits treatment. Here, berberine (BBR) and verteporfin (VER) were co-loaded into nanomicelles (BV NMs) through sonication-assisted self-assembly of PEG-g-(PVAc-co-PVCL), creating a “microenvironment remodeling—PDT potentiation—immune activation” strategy. BV NMs had a hydrodynamic diameter of 56.15 ± 0.30 nm. Drug loading lowered the critical micelle concentration from 11.2 μg/mL (blank micelles) to an apparent 1.3 μg/mL (BV NMs), supporting dilution stability. It also enhanced aqueous dispersibility, cellular uptake, and intratumoral accumulation. Mechanistically, BBR reduced mitochondrial complex I-associated activity, intracellular adenosine triphosphate levels, and extracellular lactate accumulation, attenuated cellular hypoxia and hypoxia-inducible factor-1α responses, and increased intracellular oxygen availability. Before irradiation, VER suppressed Yes-associated protein signaling and vascular endothelial growth factor expression, providing light-independent antitumor and antiangiogenic regulation. Under 660 nm irradiation, VER induced reactive oxygen species accumulation, mitochondrial depolarization, tumor-cell death, and immunogenic cell death. In vivo, BV NMs combined with irradiation achieved an approximately 96% inhibition rate based on terminal tumor weight. Proportions of mature dendritic cells in tumor-draining lymph nodes and splenic CD8+ T cells reached 3.33 and 2.73 times the control levels, respectively, alongside expansion of memory CD8+ T-cell populations. Treatment also reduced experimental pulmonary metastatic burden, achieved 50% survival at day 60, and caused no evident short-term systemic toxicity. This platform couples metabolic and angiogenic regulation with oxygen-dependent PDT and antitumor immunity, providing a strategy against primary and metastatic tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Fujian Medical University, Fuzhou350122, China.
- Department of Pharmacy, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou350025, China.
- School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou350122, China.
ORCID-Profile: Lingjun Zeng, Xin Zhou
Förderung
- Natural Science Foundation of Fujian Province
- Fujian Provincial Department of Science and Technology
Zitieren
APA
Kang, B., Zheng, D., Zeng, L., Gao, W., Xiao, L., Shi, X., & Zhou, X. (2026). Berberine/Verteporfin Nanomicelles Enable O2-Economized Photodynamic Immunotherapy in Esophageal Cancer Via Tumor Metabolic Remodeling. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c17195
Vancouver
Kang B, Zheng D, Zeng L, Gao W, Xiao L, Shi X, et al. Berberine/Verteporfin Nanomicelles Enable O2-Economized Photodynamic Immunotherapy in Esophageal Cancer Via Tumor Metabolic Remodeling. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c17195
BibTeX
@article{Kang2026,
author = {Kang, Bingkun and Zheng, Da and Zeng, Lingjun and Gao, Wenhao and Xiao, Longyun and Shi, Xiaoting and Zhou, Xin},
title = {Berberine/Verteporfin Nanomicelles Enable O2-Economized Photodynamic Immunotherapy in Esophageal Cancer Via Tumor Metabolic Remodeling},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c17195}
}
EUVIMED